Perekhrestenko T, Diachenko M, Sviezhentseva I, Gordienko A, Bilko D
1SI "Institute of Hematology and Transfusiology of the NAMS of Ukraine", Kyiv; 2National University "Kyiv-Mohyla Academy", Center for Molecular and Cell Research, Kyiv, Ukraine.
Georgian Med News. 2015 Mar(240):43-50.
Up to date, two major mechanisms have been proposed as an explanation for myeloid cells expansion in chronic myeloid leukemia (CML). One is a reduced susceptibility of hematopoietic stem or progenitor cells to apoptosis, while the other one is an increased activity within the hematopoietic progenitor cell population. The aim of the study was to identify specific features of functional activity, proliferation rates and differentiation potential of CML hematopoietic progenitor cells of patients treated with tyrosine kinase inhibitors (TKI) by identifying number of Ki-67, Bcl-2 and CD34 positive cells in bone marrow, as well as in vitro colony-forming unit assay in patients with different response to the TKI therapy. Our results indicated that there was a significant decline in proliferation activity of HSCs and HPCs in group of patients with optimal response to the TKI therapy. Correlation analysis, performed on individual basis for patients independently of response to the TKI therapy demonstrated that there was a negative correlation (ρ=0.7648) between the number of Ki67+ and CD34+ cells. As to colony to cluster ratio our results showed, that there is a correlation (ρ=0.6783) between CCR index and number of bone marrow cells with Philadelphia chromosome. It was indicated, that index of maturation correlates with level of bone marrow cells, containing Philadelphia chromosome, so as with percentage of CD34+, Bcl-2+, Pgp-170+ and Ki67+ cells in bone marrow of CML patients. In summary, obtained results suggest that different mechanisms (bcr-abl dependent and independent) may be involved in CML progression process in the same time. Disease prognosis should be preferably carried out on an individual basis.
迄今为止,已提出两种主要机制来解释慢性髓性白血病(CML)中髓系细胞的扩增。一种是造血干细胞或祖细胞对凋亡的敏感性降低,另一种是造血祖细胞群体内活性增加。本研究的目的是通过确定骨髓中Ki-67、Bcl-2和CD34阳性细胞的数量,以及对酪氨酸激酶抑制剂(TKI)治疗有不同反应的患者的体外集落形成单位测定,来识别接受TKI治疗的CML患者造血祖细胞的功能活性、增殖率和分化潜能的特定特征。我们的结果表明,对TKI治疗有最佳反应的患者组中,造血干细胞和造血祖细胞的增殖活性显著下降。对独立于TKI治疗反应的患者进行的个体相关性分析表明,Ki67+和CD34+细胞数量之间存在负相关(ρ=0.7648)。关于集落与簇的比例,我们的结果显示,CCR指数与含有费城染色体的骨髓细胞数量之间存在相关性(ρ=0.6783)。结果表明,成熟指数与含有费城染色体的骨髓细胞水平相关,与CML患者骨髓中CD34+、Bcl-2+、Pgp-170+和Ki67+细胞的百分比也相关。总之,获得的结果表明,不同机制(bcr-abl依赖性和非依赖性)可能同时参与CML的进展过程。疾病预后最好在个体基础上进行。